Antipsychotic agents: Efficacy and safety in schizophrenia

Drug, Healthcare and Patient Safety

Volumn 4, Issue 1, 2012, Pages 173-180

  de Araújo, Arão Nogueira ^a   de Sena, Eduardo Pondé ^a   de Oliveira, Irismar Reis ^a   Juruena, Mario F ^b  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antipsychotic agents; Pharmacology; Safety; Schizophrenia

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SERTINDOLE; SULPIRIDE; ZIPRASIDONE; ZOTEPINE;

AUTISM; BIPOLAR DEPRESSION; BIPOLAR MANIA; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; COST UTILITY ANALYSIS; DEPRESSION; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG BINDING SITE; DRUG EFFICACY; DRUG FATALITY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE METABOLISM; HEART ARRHYTHMIA; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; MAJOR DEPRESSION; MENTAL PATIENT; META ANALYSIS (TOPIC); METABOLIC DISORDER; METABOLIC SYNDROME X; NEGATIVE SYNDROME; OBESITY; PATIENT COMPLIANCE; PATIENT PREFERENCE; POSITIVE SYNDROME; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL WELL BEING; PSYCHOSIS; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL INTERACTION; SOMNOLENCE; TARDIVE DYSKINESIA; TORSADE DES POINTES; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 84870444244     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/DHPS.S37429     Document Type: Review

References (108)

1. Buckley PF. Treatment of schizophrenia: let's talk dollars and sense. Am J Manag Care. 1998;4(3):369-383.
2. Rice DP. The economic impact of schizophrenia. J Clin Psychiatry. 1999;60 Suppl 1:4-6; discussion 28-30.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC: American Psychiatric Association; 1994.
4. Lindenmayer JP, Bernstein-Hyman R, Grochowski S. Five-factor model of schizophrenia. Initial validation. J Nerv Ment Dis. 1994;182(11):631-638.
5. Breier A, Berg PH. The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome. Biol Psychiatry. 1999;46(3):361-364.
6. Appelbaum PS, Robbins PC, Roth LH. Dimensional approach to delusions: comparison across types and diagnoses. Am J Psychiatry. 1999;156(12):1938-1943.
7. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr Res. 2009;110(1-3):1-23.
8. Kitamura T, Okazaki Y, Fujinawa A, Takayanagi I, Kasahara Y. Dimensions of schizophrenic positive symptoms: an exploratory factor analysis investigation. Eur Arch Psychiatry Clin Neurosci. 1998;248(3):130-135.
9. Foussias G, Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr Bull. 2010;36(2):359-369.
10. Lindenmayer JP, Brown E, Baker RW, et al. An excitement subscale of the Positive and Negative Syndrome Scale. Schizophr Res. 2004;68(2-3):331-337.
11. Saykin AJ, Gur RC, Gur RE, et al. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry. 1991;48(7):618-624.
12. Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antip- sychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003;160(8):1396-1404.
13. McCreadie RG, Srinivasan TN, Padmavati R, Thara R. Extrapyramidal symptoms in unmedicated schizophrenia. J Psychiatr Res. 2005;39(3):261-266.
14. Marder SR, Glynn SM, Wirshing WC, et al. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry. 2003;160(8):1405-1412.
15. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second- generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41.
16. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152-163.
17. de Oliveira IR, Juruena MF. Treatment of psychosis: 30 years of progress. J Clin Pharm Ther. 2006;31(6):523-534.
18. Herz MI, Marder SR. Schizophrenia: Comprehensive Treatment and Management. Philadelphia: Lippincott Williams and Wilkins; 2002.
19. Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd ed. New York: Cambridge University Press; 2008.
20. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov. 2004;3(4):353-359.
21. de Oliveira IR, Elkis H, Gattaz WF, et al. Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol. CNS Spectr. 2009;14(2):93-102.
22. Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des. 2010;16(5):488-501.
23. Kerwin RW, Osborne S. Antipsychotic drugs. Medicine. 2000;28:23-25.
24. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
25. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10(1):79-104.
26. Ayuso-Gutiérrez JL, del Río Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res. 1997;28(2-3):199-206.
27. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002;63(12):1121-1128.
28. Thieda P, Beard S, Richter A, Kane J. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv. 2003;54(4):508-516.
29. Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005;3:21.
30. Harvey PD, Rabinowitz J, Eerdekens M, Davidson M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry. 2005;162(10):1888-1895.
31. Rabinowitz J, Harvey PD, Eerdekens M, Davidson M. Premorbid functioning and treatment response in recent-onset schizophrenia. Br J Psychiatry. 2006;189:31-35.
32. Meltzer HY, Rabinowitz J, Lee MA, et al. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am J Psychiatry. 1997;154(4):475-482.
33. Uçok A, Polat A, Genç A, Cakir S, Turan N. Duration of untreated psychosis may predict acute treatment response in first-episode schizophrenia. J Psychiatr Res. 2004;38(2):163-168.
34. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005;162(10):1785-1804.
35. Aleman A, Kahn RS, Selten JP. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry. 2003;60(6):565-571.
36. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry. 2003;160(11):2063-2065.
37. Leucht S, Busch R, Kissling W, Kane JM. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry. 2007;68(3):352-360.
38. Kinon BJ, Chen L, Ascher-Svanum H, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res. 2008;102(1-3):230-240.
39. Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs. 2009;23(8):649-659.
40. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63(10):1079-1087.
41. Kemp AS, Schooler NR, Kalali AH, et al. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull. 2010;36(3):504-509.
42. Kinon BJ, Potts AJ, Watson SB. Placebo response in clinical trials with schizophrenia patients. Curr Opin Psychiatry. 2011;24(2):107-113.
43. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287(14):1840-1847.
44. Thase ME. The small specific effects of antidepressants in clinical trials: what do they mean to psychiatrists? Curr Psychiatry Rep. 2011;13(6):476-482.
45. McMahon RP, Kelly DL, Boggs DL, et al. Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research. Schizophr Bull. 2008;34(2):292-301.
46. Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry. 2005;62(12):1305-1312.
47. Leber P. The use of placebo control groups in the assessment of psychiatric drugs: an historical context. Biol Psychiatry. 2000;47(8):699-706.
48. Aras G. Superiority, noninferiority, equivalence, and bioequivalence-revisited. Drug Inf J. 2001;35:1157-1164.
49. Streiner DL. Alternatives to placebo-controlled trials. Can J Neurol Sci. 2007;34 Suppl 1:S37-S41.
50. Oliveira IR, Nunes PM, Coutinho DM, Sena EP. Review of the efficacy of placebo in comparative clinical trials between typical and atypical antipsychotics. Rev Bras Psiquiatr. 2009;31(1):52-56.
51. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:10(3):799-812.
52. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
53. Correll CU, Kishimoto T, Nielsen J, Kane JM. Quantifying clinical relevance in the treatment of schizophrenia. Clin Ther. 2011;33(12): B16-B39.
54. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry. 2005;187:366-371.
55. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res. 2005;79(2-3):231-238.
56. Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology. 2006;31(10):2318-2325.
57. Leucht S, Kane JM. Measurement-based psychiatry: definitions of response, remission, stability, and relapse in schizophrenia. J Clin Psychiatry. 2006;67(11):1813-1814.
58. Levine SZ, Rabinowitz J, Engel R, Etschel E, Leucht S. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr Res. 2008;98(1-3):318-322.
59. Guy W. Clinical global impressions. In: Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
60. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441-449.
61. Andreasen NC. The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: The University of Iowa; 1984.
62. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl. 1989;7:49-58.
63. Dellva MA, Tran P, Tollefson GD, Wentley AL, Beasley CM Jr. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv. 1997;48(12):1571-1577.
64. Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley CM Jr. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry. 1998;172:499-505.
65. Csernansky JG, Mahmoud R, Brenner R; for Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346(1):16-22.
66. de Sena EP, Santos-Jesus R, Miranda-Scippa A, Quarantini Lde C, Oliveira IR. Relapse in patients with schizophrenia: a comparison between risperidone and haloperidol. Rev Bras Psiquiatr. 2003;25(4):220-223.
67. Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005;162(5):947-953.
68. Peuskens J, Trivedi J, Malyarov S, et al. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients. Psychiatry (Edgmont). 2007;4(11):34-50.
69. Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended- release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007;27(1):6-14.
70. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990;3(4):247-251.
71. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology (Berl). 2002;162(1):3-10.
72. de Haan L, Nimwegen L, Amelsvoort T, Dingemans P, Linszen D. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry. 2008;41(4):125-128.
73. Juruena MF, de Sena EP, de Oliveira IR. Safety and tolerability of antipsychotics: focus on amisulpride. Drug Healthc Patient Saf. 2010;2:205-211.
74. Janssen B, Gaebel W, Haerter M, Komaharadi F, Lindel B, Weinmann S. Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders. Psychopharmacology (Berl). 2006;187(2):229-236.
75. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv. 2000;51(2):216-222.
76. Voruganti L, Cortese L, Owyeumi L, et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res. 2002;57(2-3):201-208.
77. Thomas P, Alptekin K, Gheorghe M, Mauri M, Olivares JM, Riedel M. Management of patients presenting with acute psychotic episodes of schizophrenia. CNS Drugs. 2009;23(3):93-212.
78. Pollice R, Tomassini A, Malavolta M, et al. Subjective and psychopathological response in patients under different antipsychotic treatments: are there differences in real clinical practice? J Biol Regul Homeost Agents. 2008;22(1):83-91.
79. Rocca P, Crivelli B, Marino F, Mongini T, Portaleone F, Bogetto F. Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia. Compr Psychiatry. 2008;49(2):170-176.
80. Schennach-Wolff R, Jäger M, Seemüller F, et al. Attitude towards adherence in patients with schizophrenia at discharge. J Psychiatr Res. 2009;43(16):1294-1301.
81. Diaz E, Neuse E, Sullivan MC, Pearsall HR, Woods SW. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry. 2004;65(3):354-360.
82. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50(1-2):79-88.
83. Narvaez JM, Twamley EW, McKibbin CL, Heaton RK, Patterson TL. Subjective and objective quality of life in schizophrenia. Schizophr Res. 2008;98(1-3):201-208.
84. Huppert JD, Weiss KA, Lim R, Pratt S, Smith TE. Quality of life in schizophrenia: contributions of anxiety and depression. Schizophr Res.2001;51(2-3):171-180.
85. Kim JH, Ann JH, Kim MJ. Relationship between improvements of subjective well-being and depressive symptoms during acute treatment of schizophrenia with atypical antipsychotics. J Clin Pharm Ther. 2011;36(2):172-178.
86. Hansson L. Determinants of quality of life in people with severe mental illness. Acta Psychiatr Scand Suppl. 2006;429:46-50.
87. Eack SM, Newhill CE. Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull. 2007;33(5):1225-1237.
88. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13(1):177-183.
89. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995;10 Suppl 3:133-138.
90. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-483.
91. EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208.
92. Leon AC, Olfson M, Portera L, Farber L, Sheehan DV. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med. 1997;27(2):93-105.
93. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165(2):203-213.
94. Ventura J, Cienfuegos A, Boxer O, Bilder R. Clinical global impression of cognition in schizophrenia (CGI-CogS): reliability and validity of a co-primary measure of cognition. Schizophr Res. 2008;106(1):59-69.
95. Pietrzak RH, Olver J, Norman T, Piskulic D, Maruff P, Snyder PJ. A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. J Clin Exp Neuropsychol. 2009;31(7):848-859.
96. Collie A, Darekar A, Weissgerber G, et al Cognitive testing in early-phase clinical trials: development of a rapid computerized test battery and application in a simulated Phase I study. Contemp Clin Trials. 2007;28(4):391-400.
97. Keefe RS, Poe M, Walker TM, Kang JW, Harvey PD. The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. Am J Psychiatry. 2006;163(3):426-432.
98. Wilk CM, Gold JM, Bartko JJ, et al. Test-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia. Am J Psychiatry. 2002;159(5):838-844.
99. Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68(2-3):283-297.
100. Hurford IM, Marder SR, Keefe RS, Reise SP, Bilder RM. A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians. Schizophr Bull. 2011;37(3):538-545.
101. Kraus MS, Keefe RS. Cognition as an outcome measure in schizophrenia. Br J Psychiatry Suppl. 2007;50:s46-s51.
102. Nielsen RE, Nielsen J. Antipsychotic drug treatment for patients with schizophrenia: theoretical background, clinical considerations and patient preferences. Clin Med Ther. 2009;1:1053-1068.
103. Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry. 2002;63 Suppl 13:5-11.
104. Juruena MF, de Sena EP, de Oliveira IR. Specific mechanism of action of amisulpride in the treatment of schizophrenia and correlation with clinical response and tolerability. J Receptor Ligand Channel Res. 2011;4:49-55.
105. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry. 2001;158(3):360-369.
106. Henderson DC, Miley K. Glucose intolerance and diabetes in patients with schizophrenia. In: Meyer JM, Nasrallah HA, editors. Medical Illness and Schizophrenia. 2nd ed. Washington, DC: American Psychiatric Publishing, Inc; 2009.
107. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225-233.
108. Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord. 2008;10(7):788-797.